CBP/p300 bromodomain inhibitor FT-7051

{
  "id": "MLC-T-ONC-012348",
  "term": "CBP/p300 bromodomain inhibitor FT-7051",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable inhibitor of the bromodomain of the histone acetyltransferase (HAT) paralogs, CREB binding protein (CBP) and p300 (E1A-associated protein p300; p300 HAT), with potential antineoplastic activity. Upon oral administration, CBP/p300 bromodomain inhibitor FT-7051 targets and binds to the bromodomain of CBP and p300. This disrupts the acetylation of histones and other proteins and prevents the co-activation of the androgen receptor (AR) including AR-v7. This may inhibit tumor cell proliferation in AR-positive tumor cells. The HAT paralogs CBP and p300 are key transcriptional co-activators that are essential for a multitude of cellular processes and are implicated in the progression and therapeutic resistance of certain cancers.",
  "synonyms": [
    "p300/CBP bromodomain inhibitor FT-7051"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/cbp-p300-bromodomain-inhibitor-ft-7051/"
}